Literature DB >> 16139140

Reversal of inappropriate peripheral vascular responses in hypertrophic cardiomyopathy.

Rajesh Thaman1, Perry M Elliott, Jaymin S Shah, Bryan Mist, Lynne Williams, Ross T Murphy, William J McKenna, Michael P Frenneaux.   

Abstract

OBJECTIVES: We assessed the frequency of abnormal forearm vasodilator responses during lower body negative pressure (LBNP) in 21 non-obstructive hypertrophic cardiomyopathy (HCM) patients (31 +/- 8 [20 to 43] years) with abnormal blood pressure response (ABPR) to exercise and the effects of three drugs used to treat vasovagal syncope (propranolol, clonidine, and paroxetine) in a double-blind crossover study.
BACKGROUND: Some HCM patients have an ABPR to exercise, which may be due to paradoxical peripheral vasodilatation. A similar proportion has paradoxical forearm vasodilatation during central volume unloading using LBNP. These abnormal reflexes may be caused by left ventricular mechanoreceptor activation. Similar mechanisms may also contribute to some cases of vasovagal syncope.
METHODS: Blood pressure changes were assessed during exercise, and forearm vascular responses and baroreceptor sensitivity were assessed during LBNP using plethysmography.
RESULTS: Nine (43%) patients (group A) had paradoxical vasodilator responses (forearm vascular resistance [FVR] fell by 7.5 +/- 4.6 U), and 12 (57%) patients (group B) had normal vasoconstrictor responses during LBNP (FVR increased by 7.7 +/- 4.9 U). Paroxetine augmented systolic blood pressure (SBP) during exercise in group A (21 +/- 6 mm Hg vs. 14 +/- 11 mm Hg at baseline, p = 0.02); no effect was detected in group B. Paroxetine reversed paradoxical vascular responses during LBNP in seven (78%) patients from group A. Propranolol and clonidine had no significant effect on SBP during exercise but reversed paradoxical vascular responses in some patients from group A (n = 5 and n = 3).
CONCLUSIONS: Paradoxical vasodilatation during LBNP occurs in 40% of patients with ABPR during exercise and is reversed by propranolol, clonidine, and paroxetine. Paroxetine also improved SBP response to exercise.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16139140     DOI: 10.1016/j.jacc.2005.05.053

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  8 in total

1.  Relation of pulse pressure to blood pressure response to exercise in patients with hypertrophic cardiomyopathy.

Authors:  Kevin S Heffernan; Martin S Maron; Eshan A Patvardhan; Richard H Karas; Jeffrey T Kuvin
Journal:  Am J Cardiol       Date:  2010-12-22       Impact factor: 2.778

Review 2.  Insights and challenges in hypertrophic cardiomyopathy, 2012.

Authors:  Srijita Sen-Chowdhry; María Teresa Tomé Esteban; William J McKenna
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2012-09-25

3.  Shortening baroreflex delay in hypertrophic cardiomyopathy patients -- an unknown effect of β-blockers.

Authors:  Agnieszka Katarzynska-Szymanska; Romuald Ochotny; Zofia Oko-Sarnowska; Hanna Wachowiak-Baszynska; Tomasz Krauze; Jaroslaw Piskorski; Adrian Gwizdala; Przemyslaw Mitkowski; Przemyslaw Guzik
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

4.  Head-Up Tilt Test in Risk Stratification of Patients with Hypertrophic Cardiomyopathy.

Authors:  Hana Sediva; T Hnat; J Bonaventura; J Slesarenko; J Veselka
Journal:  Int J Angiol       Date:  2019-06-16

5.  Effects of lifestyle changes and high-dose β-blocker therapy on exercise capacity in children, adolescents, and young adults with hypertrophic cardiomyopathy.

Authors:  Ewa-Lena Bratt; Ingegerd Östman-Smith
Journal:  Cardiol Young       Date:  2014-03-10       Impact factor: 1.093

6.  Transcatheter mitral valve repair for the treatment of severe mitral regurgitation and exertional pre-syncope in a patient with non-obstructive hypertrophic cardiomyopathy: a case report.

Authors:  Katya Lucarelli; Federica Troisi; Maria Scarcia; Massimo Grimaldi
Journal:  Eur Heart J Case Rep       Date:  2021-11-17

Review 7.  Update on hypertrophic cardiomyopathy and a guide to the guidelines.

Authors:  Srijita Sen-Chowdhry; Daniel Jacoby; James C Moon; William J McKenna
Journal:  Nat Rev Cardiol       Date:  2016-09-29       Impact factor: 32.419

8.  Biventricular pacemaker therapy improves exercise capacity in patients with non-obstructive hypertrophic cardiomyopathy via augmented diastolic filling on exercise.

Authors:  Ibrar Ahmed; Brodie L Loudon; Khalid Abozguia; Donnie Cameron; Ganesh N Shivu; Thanh T Phan; Abdul Maher; Berthold Stegemann; Anthony Chow; Howard Marshall; Peter Nightingale; Francisco Leyva; Vassilios S Vassiliou; William J McKenna; Perry Elliott; Michael P Frenneaux
Journal:  Eur J Heart Fail       Date:  2020-01-23       Impact factor: 17.349

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.